Close X
Attorney Spotlight

What is Shannon Wiley looking forward to at this year's Asembia Specialty Pharmacy Summit? Find out more>


Close X


Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Download the Healthcare Fraud & Abuse Review 2017, authored by Bass, Berry & Sims

The Healthcare Fraud & Abuse Review 2017 details all healthcare-related False Claims Act settlements from last year, organized by particular sectors of the healthcare industry. In addition to reviewing all healthcare fraud-related settlements, the Review includes updates on enforcement-related litigation involving the Stark Law and Anti-Kickback Statute, and looks at the continued implications from the government's focus on enforcement efforts involving individual actors in connection with civil and criminal healthcare fraud investigations.

Click here to download the Review.

Chris Lazarini Discusses Heightened Pleading Standard Under Rule 9(b)

Securities Litigation Commentator


March 14, 2017

Bass, Berry & Sims attorney Chris Lazarini discussed the heightened pleading standard for claims of fraud under Rule 9(b) in an auction rate securities case. 

Chris provided the analysis for Securities Litigation Commentator (SLC). The full text of the analysis is below and used with permission from the publication. If you would like to receive additional content from the SLC, please visit the SLC website to sign up for the newsletter.

William Beaumont Hospital System vs. Morgan Stanley & Co., LLC, No. 16-1135 (6th Cir., 1/26/17) 

Under Rule 9(b)'s heightened pleading standard, claims of fraud must state with particularity: (1) the statements Plaintiff contends were fraudulent, (2) the identity of the speaker, (3) where and when the statements were made, and (4) an explanation of why the statements were fraudulent. 

In 2006, the parties entered into bond purchase agreements and an interest rate swap agreement for Plaintiff's auction rate securities ("ARS") issuance, which Defendants would underwrite and auction. In late 2007, the ARS market collapsed. Defendants initially submitted covering bids to support Plaintiff's ARS sales, but stopped doing so in early 2008. To avoid a failed auction, Plaintiff was forced to pay investors interest rates higher than anticipated. In 2014, Plaintiff sued, alleging that Defendants omitted material information about the ARS market, their cover bidding process and the availability of different interest rate structures, and failed to warn Plaintiff about the deteriorating ARS market in 2007 and 2008. The district court dismissed, finding Michigan's six-year statute of limitations on Plaintiff's common law fraud claims had run, and Plaintiff failed to state a claim for relief under FRCP 12(b)(6) (see SLA 2016-06).

Conducting a de novo review, the Sixth Circuit affirms the 12(b)(6) dismissal, because Plaintiff failed to meet FRCP 9(b)’s heightened pleading standards. First, the Court rejects Plaintiff's claim that Defendants failed to disclose their ability to stop making cover bids, pointing out that Plaintiff acknowledged Defendants' right to do so in its 2006 ARS Official Statement. Second, the Court finds Plaintiff's allegations regarding alternative interest rate structures too vague because Plaintiff failed to describe the time, place, speaker and content of the alleged fraud. Plaintiff's failure to warn claims, the Court concludes, fail for the same reason and because the volatility in the ARS market was "widely-known" in the financial markets. Finally, Defendants had no duty to provide ongoing disclosures about the ARS market, and without that duty, there can be no fraud by omission. Because the Court affirms on 12(b)(6) grounds, it declines to address the statute of limitations issues. 

Goldman Sachs was also a Defendant.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.